title: Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects.
abstract: OBJECTIVE
  Revaprazan is a novel acid pump antagonist. The aim of this study was to investigate the inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects.
  
  
  METHODS
  In a double-blind, three-way cross-over study, 30 healthy male volunteers were randomized to 100, 150 or 200 mg of oral revaprazan daily for 7 days. Serum gastrin concentration was measured, and 24-h intragastric pH was recorded at baseline and on days 1 and 7 of each administration period. Serial blood samples were processed for pharmacokinetics.
  
  
  RESULTS
  Median intragastric pH over 24 h and mean percentage time that pH was > 4 increased in a dose-dependent manner and were significantly higher on days 1 and 7 compared with baseline in all groups (P < 0.05). The antisecretory effect of revaprazan was rapid and nearly maximal on day 1 in all groups. Serum gastrin levels were rapidly normalized by 100 and 150 mg/day of revaprazan on days 1 and 7, but were significantly higher in the 200 mg/day revaprazan group. The pharmacokinetic effect was rapidly absorbed and eliminated on days 1 and 7 in all groups.
  
  
  CONCLUSIONS
  Revaprazan rapidly and effectively inhibits gastric acid secretion in healthy male subjects. Therefore, revaprazan can be used as an effective drug for acid-related disease.
authors.affiliation: Division of Gastroenterology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Yeongdeungpo-gu, Seoul.
authors.forename: Hyung-Keun
authors.initials: HK
authors.lastname: Kim
authors.forename: Soo-Heon
authors.initials: SH
authors.lastname: Park
authors.forename: Dae-Young
authors.initials: DY
authors.lastname: Cheung
authors.forename: Young-Seok
authors.initials: YS
authors.lastname: Cho
authors.forename: Jin-Il
authors.initials: JI
authors.lastname: Kim
authors.forename: Sung-Soo
authors.initials: SS
authors.lastname: Kim
authors.forename: Hiun-Suk
authors.initials: HS
authors.lastname: Chae
authors.forename: Jae-Kwang
authors.initials: JK
authors.lastname: Kim
authors.forename: In-Sik
authors.initials: IS
authors.lastname: Chung
mesh_terms: D000328:Adult; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004942:Esophagitis, Peptic / Q000188:drug therapy* / Q000378:metabolism; D005500:Follow-Up Studies; D005744:Gastric Acid / Q000378:metabolism*; D005745:Gastric Acidity Determination; D005753:Gastric Mucosa / Q000378:metabolism*; D006801:Humans; D008297:Male; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000378:metabolism; D054328:Proton Pump Inhibitors / Q000008:administration & dosage*; D012016:Reference Values; D013270:Stomach / Q000187:drug effects
chemical_list: D054328:Proton Pump Inhibitors